Andi Salsabilah, . (2020) POTENSI PEMBERIAN SEL PUNCA MESENKIMAL (Mesenchymal Stem Cells) SEBAGAI TERAPI IMUNOMODULATOR PADA PERBAIKAN PARU PASIEN PNEUMONIA COVID-19: Systematic Review. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
Text
ABSTRAK.pdf Download (229kB) |
|
Text
AWAL.pdf Download (579kB) |
|
Text
BAB.1.pdf Download (342kB) |
|
Text
BAB.2.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
BAB.3.pdf Restricted to Repository UPNVJ Only Download (545kB) |
|
Text
BAB.4.pdf Restricted to Repository UPNVJ Only Download (407kB) |
|
Text
BAB.5.pdf Download (314kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (437kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (185kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (2MB) |
|
Text
ARTIKEL KI .pdf Restricted to Repository staff only Download (492kB) |
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of a positive and single-stranded RNA virus and originates from the genus Coronaviridae. On March 11, 2020, WHO declared the SARS-CoV-2 epidemic virus to become a pandemic due to an increase in cases of 126,063 positive people, 67,071 recoveries, and 4,616 deaths. Until now, there has been no specific treatment, such as antivirals or vaccines for COVID-19 patients, so there is a need for innovative therapeutic strategies to treat COVID-19 patients, one of which is by presenting stem cell therapy based on Mesenchymal Stem Cells (MSCs). Methods: Systematic Review by conducting literature searches using Google Scholar, PubMed, and Science Direct. The literature search method used PICO (Population, Intervention, Comparison, Outcome) is based on clinical trials in COVID-19 patients using experimental and observational research designs. Results: Based on four studies, 40 patient samples showed a proportion of 100% improvement in the lungs in patients who had complications of Acute Respiratory Distress Syndrome (ARDS) from increased serum cytokine IL-10, decreased IL-6, increased number of peripheral mononuclear cells, and decreased C-reactive protein. Conclusion: MSCs have an immunomodulating capacity to prevent cytokine storm processes in SARS-CoV-2 infection and improve lung organs in COVID-19 patients.
Item Type: | Thesis (Skripsi) |
---|---|
Additional Information: | [No. Panggil: 1710211086] [Pembimbing: Yudhi Nugraha] [Penguji: Yanto Sandy Tjang] |
Uncontrolled Keywords: | Mesenchymal Stem Cells, Pneumonia COVID-19, SARS-COV-2, ARDS |
Subjects: | R Medicine > RM Therapeutics. Pharmacology |
Divisions: | Fakultas Kedokteran > Program Studi Kedokteran (S1) |
Depositing User: | Andi Salsabilah |
Date Deposited: | 09 Mar 2021 09:40 |
Last Modified: | 21 Jan 2022 03:08 |
URI: | http://repository.upnvj.ac.id/id/eprint/9263 |
Actions (login required)
View Item |